Drug Trial Radar · NCT07098988
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Mar 31, 2029
Study completion Mar 31, 2031
Sponsor
- Lead sponsor
- CatalYm GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).
Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Adult Solid Tumor
Interventions
VisugromabBiological
Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
Matching placebo for visugromabDrug
Participants receive Matching Placebo intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
Pembrolizumab 200 mg Q3WBiological
Participants receive Pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion.
Pemetrexed 500 mg/m^2Drug
Participants receive Pemetrexed 500 mg/m\^2 IV on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
Carboplatin AUC 5Drug
Participants receive Carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) on Day 1 of each 21-day cycle for four cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: up to 24 months
Locations
51 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Smilow Cancer Center, Derby
Derby, Connecticut · Recruiting
Smilow Cancer Center, Guilford
Guilford, Connecticut · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital - North Haven
North Haven, Connecticut · Recruiting
Smilow Cancer Hospital - Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital - Waterbury
Waterbury, Connecticut · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Longone Health
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Thorax Clinic Heidelberg
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
University Hospital Würzburg
Würzburg, Bavaria, Germany · Recruiting
Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift
Bielefeld, North Rhine-Westphalia, Germany · Recruiting
Clinics Essen-Mitte
Essen, North Rhine-Westphalia, Germany · Recruiting
Foundation Bethanien Moers
Moers, North Rhine-Westphalia, Germany · Recruiting
Großhansdorf Hospital - Clinical Center for Pulmonology and Thoracic Surgery, Department of Thoracic Oncology
Großhansdorf, Schleswig-Holstein, Germany · Recruiting
Oncology Reference Center
Aviano, Italy · Recruiting
Local Health Unit of Romagna - Santa Maria delle Croci Hospital of Ravenna, Onco-Hematology Department
Ravenna, Italy · Recruiting
National Cancer Institute Regina Elena, IRCCS
Rome, Italy · Recruiting
Institute of Cancer Research and Treatment of Candiolo
Candiolo, Candiolo, Italy · Recruiting
Institute of Romagna for Cancer Research " Dino Amadori" - IRCCS IRST
Meldola, Forli, Italy · Recruiting
National Cancer Institute, IRCCS
Milan, Milan, Italy · Recruiting
MED-Polonia, Sp. z o.o. (LLC)
Poznan, Poland · Recruiting
Specialist Hospital in Prabuty Sp. z o.o. (LLC), Department of Pulmonology
Prabuty, Poland · Recruiting
University Teaching Hospital No. 4 in Lublin, Multi-Profile Non-Invasive Treatment Department
Lublin, Lublin Voivodeship, Poland · Recruiting
Gral Medical S.R.L. - Oncofort Hospital
Piteşti, Romania · Recruiting
Clinica Polisano S.R.L.
Sibiu, Romania · Recruiting
SC Oncomed SRL, Department of Medical Oncology
Timișoara, Romania · Recruiting
"Sf. Nectarie" Oncology Center, Department of Medical Oncology
Craiova, Dolj, Romania · Recruiting
University Hospital Lucus Augusti (HULA)
Lugo, Spain · Recruiting
MD Anderson International Cancer Center Spain
Madrid, Spain · Recruiting
University Hospital of Jaen
Jaén, Andalusia, Spain · Recruiting
Regional University Hospital of Malaga
Málaga, Andalusia, Spain · Recruiting
University Hospital Virgen Macarena
Seville, Andalusia, Spain · Recruiting
University Hospital Virgen del Rocio (HUVR)
Seville, Andalusia, Spain · Recruiting
University Hospital Marques de Valdecilla (HUMV)
Santander, Cantabria, Spain · Recruiting
Hospital del Mar
Barcelona, Catalonia, Spain · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.